Manager TitleAgeSince
Chief Executive Officer 62 01/02/2023
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 55 01/08/2017
Director TitleAgeSince
Chairman 63 17/01/2023
Chairman 78 -
Director/Board Member 63 01/01/2004
Change 5-day change 1-year change 3-year change Capi.($)
-4.44%+21.43% - - 6.31M
+0.39%-3.06%+26.17%+12.80% 225B
-0.41%-2.95%+4.95%-19.76% 148B
-0.32%+0.80%-16.13%+20.26% 131B
-2.29%+1.22%-56.07%-11.37% 70.1B
-0.97%-0.11%+10.63%+18.28% 52.35B
-1.65%-1.15%-16.82%-14.83% 50.91B
-1.29%-5.05%+19.57%+26.11% 42.68B
-0.16%-2.17%+42.08%+49.13% 40.5B
-0.78%-2.65%-14.74%+49.15% 33.3B
Average -1.14%-1.55%-0.04%+14.42% 88.2B
Weighted average by Cap. -0.46%-2.12%+2.92%+8.53%

Financials

2024 2025
Net sales 10.51M 1.1M 947K 888K 813K 1.52M 104M 1.53M 4.09M 53.16M 4.13M 4.04M 171M 16.65M 1.74M 1.5M 1.41M 1.29M 2.4M 165M 2.42M 6.48M 84.19M 6.54M 6.4M 271M
Net income -20.18M -2.11M -1.82M -1.71M -1.56M -2.91M -200M -2.94M -7.86M -102M -7.93M -7.76M -329M -17.52M -1.83M -1.58M -1.48M -1.35M -2.53M -173M -2.55M -6.82M -88.61M -6.89M -6.74M -285M
Net Debt - -
Logo Phase Holographic Imaging PHI AB
Phase Holographic Imaging PHI AB (PHI) is a Sweden-based company active in the field of medical technology. It develops and markets time-lapse cytometers for clinical applications. The products use holographic microscopy technology, with image sensors capturing light information from objects, and computer processing the information to create visual image. It is also engaged in the development of related software. Its method allows to view and measure living cell over time, without disturbing or destroying it. PHI collaborates with cancer- and stem cell researchers, among others. The Company’s product portfolio includes HoloMonitor M3, a bench-top time-lapse cytometer, and HoloMonitor M4, allowing cell analysis in the cultivation incubator.
Employees
15